Form 4: Vaxcyte CEO Grant Pickering Sells Shares Under 10b5-1 Trading Plan

Vaxcyte's CEO, Grant Pickering, executed multiple sales of common stock on November 1, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Grant Pickering, the CEO of Vaxcyte, Inc., reported the sale of common stock on November 1, 2024.
• The sales were executed under a Rule 10b5-1 trading plan adopted on April 12, 2024.
• A total of 9,955 shares were sold at a weighted average price of $106.35, with prices ranging from $105.855 to $106.80.
• An additional 3,312 shares were sold at a weighted average price of $107.339, with prices ranging from $106.865 to $107.845.
• Furthermore, 1,733 shares were sold at a weighted average price of $108.5, with prices ranging from $107.97 to $108.93.
• Following these transactions, Pickering directly owns 435,219 shares of common stock.
• Pickering also indirectly owns 138,581 shares through a children's trust for his daughter and another 138,581 shares through a children's trust for his son.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the filing simply reports stock sales under a pre-arranged plan. It doesn't inherently indicate positive or negative sentiment about the company's prospects.

Positives

• The sales were executed under a pre-arranged 10b5-1 trading plan, which is a legal and transparent way for insiders to sell shares.

Risks

• Insider selling, even under a 10b5-1 plan, can sometimes be perceived negatively by investors.

Industry Context

Insider trading activity is always closely watched in the biotech industry, as it can provide signals about management's confidence in the company's future prospects. However, pre-planned sales under 10b5-1 plans are common and often unrelated to short-term expectations.

Comparison to Industry Standards

• It's common for executives at publicly traded companies, including biotech firms like Vaxcyte, to utilize 10b5-1 trading plans to diversify their holdings and manage personal finances.
• The volume of shares sold by Grant Pickering is relatively small compared to the total outstanding shares of Vaxcyte, suggesting it's unlikely to have a significant impact on the stock price.
• Other biotech companies such as Moderna and BioNTech have also seen similar insider selling activity under 10b5-1 plans.

Stakeholder Impact

• The stock sale could have a minor impact on shareholder sentiment, but the existence of a 10b5-1 plan mitigates potential concerns.

Key Dates